Chengdu Olymvax Biopharmaceuticals Inc.

¥28.19As of Sun 8 Nov 2026, 12:00 UTC
SSE:688319Healthcare
Country China
PE (Fwd) •••
TSR 5Y CAGR (5.07%)
Div yield —
ROE (3.44%)
Biotechnology
Beta (5Y) 0.67
PE TTM —
TSR TTM 12.36%
Mkt cap ¥11.43B
ROIC (6.97%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
¥28
(1.19%)
(61.67%)
Hold 2|8|1|1|11
4Q25
1Q26
2Q26
3Q26
Earnings per share¥
0.28
0.32
0.32
0.34
5.39%
22.35%
19.86%
30.51%
Revenue¥M
589.5
598.5
590.2
619.5
3.26%
0.70%
(5.26%)
2.16%
Peers (US$1.713B)
Cap (US$)
PE
1.646B
17.38x
Capital
TTM
5Y
10Y
Leveragex
0.379
(0.041)
(0.035)
EBIT/Intx
10.53
0.056
0.055
Own earn%
(55.77)
220.76
215.73
Sh yield%
26.45
23.70
22.14
Owners
Insiders/Inst%
0.73
30.61
Short interest%
1.50
SBC / revenue%
3.43
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
1
Op margin range%
17–22
$1 testx
—
Incr. ROIC%
38